It depends on the type. Acute kidney injury, where the kidneys suddenly stop working properly, is often reversible. Chronic kidney disease, where function declines gradually over months or years, is not curable with current medicine. But “not curable” doesn’t mean “not treatable.” Modern therapies can significantly slow the progression of chronic kidney disease, sometimes holding it stable for decades.
Acute Kidney Injury Can Be Reversed
Acute kidney injury (AKI) happens when something abruptly damages the kidneys: a severe infection, a crush injury, dehydration, a drug reaction, or a sudden drop in blood flow during surgery. The kidneys essentially shut down or dramatically reduce their filtering capacity. The good news is that kidney tissue can recover from this kind of damage if the underlying cause is treated quickly.
Recovery timelines vary widely. Among patients who needed temporary dialysis after AKI, about 29% regained kidney function within three months, and roughly 31% recovered by six months, according to U.S. Renal Data System tracking. However, AKI isn’t always a clean recovery story. By six months, nearly 48% of those patients had progressed to permanent kidney failure, and about 19% had died. The severity of the initial injury matters enormously.
Even people who appear to recover fully from AKI carry long-term risk. Among patients with no prior kidney problems who were hospitalized with AKI, about 18% were diagnosed with chronic kidney disease within a year, and that number climbed to 20% by two years. Scarring can continue even after the acute episode resolves, because the cells that produce scar tissue don’t always return to their resting state. This is why follow-up kidney function testing after AKI is important, even if you feel fine.
Why Chronic Kidney Disease Can’t Be Reversed
Chronic kidney disease (CKD) involves a cycle of damage that feeds on itself. As filtering units in the kidney are destroyed, the surviving ones have to work harder, filtering more blood under higher pressure. This overwork damages them in turn, leading to more scarring and more loss. The combination of reduced blood supply, high pressure inside the kidney’s filters, and progressive scarring creates a self-reinforcing loop that the body can’t undo.
Scar tissue in the kidney doesn’t turn back into functional tissue. Once the filtering units (called nephrons) are replaced by fibrosis, they’re gone permanently. This is fundamentally different from AKI, where the damage is often to cells that can regenerate if given the chance. CKD is a structural transformation of the organ.
Treatments That Slow the Decline
While CKD can’t be reversed, the speed at which it progresses can be dramatically reduced. Several classes of medication have strong clinical evidence behind them, and using them in combination with lifestyle changes can keep many people off dialysis for years or even indefinitely.
Blood pressure medications that target a specific hormonal pathway in the kidney (ACE inhibitors and ARBs) have been a cornerstone of CKD management for decades. In one major trial, the ACE inhibitor ramipril reduced the risk of kidney function declining by 50%, needing dialysis, or dying by 22 to 38% compared with other blood pressure drugs. Another trial found that the ARB losartan reduced the risk of serious kidney outcomes by 16% in people with type 2 diabetes and CKD.
A newer class of drugs originally developed for diabetes, called SGLT2 inhibitors, has shown even more striking results. A large meta-analysis of over 38,000 patients found that these drugs reduced the combined risk of needing dialysis, transplant, or dying from kidney disease by 33% compared with placebo. The DAPA-CKD trial showed a 39% reduction in worsening kidney function, and these benefits held regardless of whether the patient had diabetes. The EMPA-KIDNEY trial confirmed similar results, with a 28% reduction in CKD progression.
A newer hormone-blocking drug, finerenone, reduced the composite risk of serious kidney events by 18% in people with CKD and type 2 diabetes who were already on standard therapy. Injectable medications originally used for diabetes (GLP-1 receptor agonists) showed a 17% reduction in a composite kidney endpoint across five major trials.
How Diet Affects Kidney Function
Reducing protein intake is one of the most studied dietary interventions for CKD. A meta-analysis of clinical trials found that low-protein diets slowed the rate of kidney function decline by about 1.85 mL/min per year compared with normal protein intake. That may sound modest, but over a decade it could represent the difference between stable kidney function and needing dialysis. Low-protein diets also reduced the risk of progressing to kidney failure by 41%.
The effect was strongest in people who already had significant protein in their urine or whose kidney function was already reduced, suggesting that dietary changes matter most once disease is established. Most studies tested protein intakes between 0.3 and 0.9 grams per kilogram of body weight per day, compared with a typical Western intake of around 1.0 to 1.2 g/kg/day. Adequate calorie intake (30 to 35 calories per kilogram per day) is essential when restricting protein to avoid muscle breakdown and malnutrition.
Beyond protein, managing sodium and potassium intake becomes increasingly important as CKD progresses, because the kidneys lose their ability to regulate these minerals. Your nephrologist or a renal dietitian can tailor recommendations based on your specific stage and lab results.
Transplant: The Closest Thing to a Cure
A kidney transplant is the most effective treatment for end-stage kidney disease, but it’s technically a replacement therapy rather than a cure. You trade one set of medical requirements for another. Instead of dialysis sessions, you take immunosuppressive medications every day for the rest of your life to prevent your immune system from attacking the new organ. These drugs carry their own risks, including increased susceptibility to infections and, ironically, a form of kidney damage caused by the anti-rejection medications themselves.
Despite these trade-offs, transplant outcomes are substantially better than staying on dialysis. Five-year survival for transplant recipients is around 80%, compared with 53% for matched patients who remain on dialysis. Transplant recipients initially face a higher risk of death in the first months after surgery, primarily from infections, but after that early period, survival rates progressively pull ahead. People who receive kidneys from living donors or standard-quality deceased donors gain a survival advantage almost immediately.
A transplanted kidney doesn’t last forever. The average lifespan of a deceased-donor kidney is 12 to 15 years, and living-donor kidneys typically last 15 to 20 years, though some function much longer. Long-term graft survival has been stubbornly difficult to improve, partly because the same drugs that prevent rejection also slowly damage the transplanted kidney through scarring and blood vessel changes.
Cell Therapy and Regenerative Approaches
Researchers are actively exploring whether stem cells and other cell-based therapies could one day regenerate damaged kidney tissue. Clinical trials are underway testing various approaches for both AKI and CKD, and early results suggest these therapies are generally safe. However, the field is still in its early stages. There’s no consensus yet on basic questions like how many cells to deliver, how to get them to the right location, or how long the effects last. These treatments are not available outside of clinical trials, and it will likely be years before any become standard care.
The practical reality today is that CKD management focuses on preservation: protecting the kidney function you still have. With the combination of modern medications, dietary adjustments, and blood pressure control, many people diagnosed with early or moderate CKD can maintain stable kidney function for years. The disease isn’t curable, but for a growing number of patients, it’s controllable.